Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of trastuzumab emtansine alone or with anti-cancer therapies
2023-503479-79-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Jun 2011
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 27
01
Overview
Phase 2, open-label trial of trastuzumab emtansine in metastasis (4 arms), sponsored by Roche. Primary endpoints: Incidence of adverse events leading to treatment discontinuation or dose reduction and Incidence of adverse events and serious adverse events. Planned start Jun 2011; status: authorised.
02
Drugs
trastuzumab emtansine
03
Conditions
metastasis
Beyond the preview
Go deeper on 2023-503479-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503479-79-00.